PolyMedix Hid Drug's Flaws Before $20M Stock Deal, Suit Says

Law360, New York (July 2, 2012, 5:21 PM EDT) -- PolyMedix Inc. was slapped with a lawsuit in Pennsylvania federal court Monday by a putative class of investors who say the experimental drug company misled the public about a flawed anti-stroke treatment in order to generate buzz for a $20 million stock offering.

The company and its top brass misled investors about clinical trials of PMX-60056, a compound intended to induce blood clotting in order to reduce the risk of stroke, according to the suit. In numerous public statements, PolyMedix executives downplayed clinical trial results linking...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

ANDERSON v. POLYMEDIX, INC. et al


Case Number

2:12-cv-03721

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Judge

MARY A. MCLAUGHLIN

Date Filed

July 2, 2012

Law Firms

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.